OCGN
Ocugen, Inc.
Key Financials
Net Income
$-67846000
↓ 25.5%
Operating Income
$-62916000
↓ 14.9%
Revenue
$4.4M
↑ 8.8%
EPS (Diluted)
$-0.26
↓ 18.2%
Total Liabilities
$55.7M
↑ 5.4%
Total Assets
$43.5M
↓ 47.2%
Shareholders' Equity
$-12166000.00
↓ 141.1%
Cash & Equivalents
$39.5M
↓ 26.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/23/2026 | View on SEC |
| 4 | 9/11/2026 | View on SEC |
| 144 | 9/9/2026 | View on SEC |
| 8-K | 9/8/2026 | View on SEC |
| DEFA14A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| DEFA14A | 7/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | OCGN |
| Company Name | Ocugen, Inc. |
| CIK | 1372299 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 484-328-4701 |